Search

Displaying results 2771 - 2780 of 10000 in total
  1. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    to general anesthesia. … Due to these risks, the use of butalbital-containing combination products is typically limited for use only in cases where other medications are deemed ineffective and such usage is advised to be carefully

  2. Drug

    Methyl aminolevulinate

    go.drugbank.com/drugs/DB00992
    ApprovedInvestigational

    Methyl aminolevulinate is a prodrug that is metabolised to Protoporphyrin IX (a photosensitizer) used in photodynamic therapy.

    Synonyms: Aminolevulinato de metilo
  3. Drug

    Methyl nicotinate

    go.drugbank.com/drugs/DB13882
    Approved

    The action of methyl nicotinate as a rubefacient is thought to involve peripheral vasodilation. … Methyl nicotinate is the methyl ester of [DB00627] that is used as an active ingredient as a rubefacient in over-the-counter topical preparations indicated for muscle and joint pain.

  4. Drug

    Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen

    go.drugbank.com/drugs/DB16709
    Approved

    at the site from which the graft is taken. … [L35505] It was developed as an alternative to autografting - the process by which a patient's own skin is harvested and grafted onto the burn site - which has the disadvantage of creating a new wound

  5. Drug

    Tinzaparin

    go.drugbank.com/drugs/DB06822
    ApprovedInvestigational

    Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. … Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa.

    Products: INNOHEP 4500 IE 0.45ML, INNOHEP 8.000 IE/0.4ML
  6. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    [A275455,L56096] By competitively blocking the glucocorticoid receptor, relacorilant prevents cortisol from activating anti-apoptotic survival pathways, thereby restoring the efficacy of cytotoxic therapies … in the context of resistant cancers.

  7. Drug

    Telotristat ethyl

    go.drugbank.com/drugs/DB12095
    Approved

    [L43342] It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt. … [A252937] The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease.[A252937]

  8. Drug

    Enoxacin

    go.drugbank.com/drugs/DB00467
    Approved

    A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.

  9. Drug

    Fencamfamin

    go.drugbank.com/drugs/DB01463
    ApprovedIllicitWithdrawn

    It is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose. … It is especially useful in patients with chronic conditions due to its favourable safety profile.

  10. Drug

    Agomelatine

    go.drugbank.com/drugs/DB06594
    ApprovedInvestigational

    In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. … Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005.

    Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists